诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

已收盘 11-11 16:08:05

11.900

-0.150

-1.24%

最高12.040	最低11.720	成交量302.70万
今开12.100	昨收12.050	日振幅2.66%
总市值210.27亿	流通市值177.79亿	总股本17.67亿
成交额3,581万	换手率0.20%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":11.9,"timestamp":1794384485010,"preClose":12.05,"halted":0,"volume":3027000,"delay":0,"changeRate":-0.012448132780083016,"floatShares":1494000000,"shares":1767000000,"eps":0.44711722384804287,"marketStatus":"已收盘","change":-0.15,"latestTime":"11-11 16:08:05","open":12.1,"high":12.04,"low":11.72,"amount":35807860,"amplitude":0.026556,"askPrice":11.9,"askSize":5000,"bidPrice":11.89,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.9021860745349413,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794447000000},"marketStatusCode":5,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":12.05,"openAndCloseTimeList":[[1794360600000,1794369600000],[1794373200000,1794384000000]],"volumeRatio":0.452369,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":25.92,"timestamp":1794380400000,"preClose":26.2,"halted":0,"volume":5075100,"delay":0,"premium":"-60.98"}},"requestUrl":"/m/hq/s/09969/wiki","defaultTab":"wiki","newsList":[{"id":"2682328438","title":"诺诚健华（688428）11月10日主力资金净卖出633.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682328438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682328438?lang=zh_cn&edition=full","pubTime":"2026-11-11 08:34","pubTimestamp":1794357299,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月10日收盘，诺诚健华报收于26.2元，下跌0.91%，换手率2.16%，成交量5.9万手，成交额1.56亿元。近5日资金流向一览见下表：诺诚健华融资融券信息显示，融资方面，当日融资买入1081.02万元，融资偿还1021.26万元，融资净买入59.75万元。诺诚健华主营业务：主要从事生物医药研发、生产和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100013620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK0239","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151586158","title":"诺诚健华：贝莱德减持，好仓比例降至4.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151586158","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151586158?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:32","pubTimestamp":1794303127,"startTime":"0","endTime":"0","summary":"贝莱德于2026年11月5日因不再持有部分股份的保证权益，通过场外交易（代价性质：非现金资产）减持诺诚健华（09969）股份406.89万股；该笔交易未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次减持前持有诺诚健华好仓7765.09万，占比5.19%；减持后持股量为7358.20万，好仓比例降至4.92%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188073609","title":"诺诚健华：贝莱德增持，好仓比例升至5.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188073609","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188073609?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:13","pubTimestamp":1794215596,"startTime":"0","endTime":"0","summary":"贝莱德于2026年11月4日通过取得股份保证权益的方式增持诺诚健华（09969）股份347.62万股，属场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有诺诚健华好仓7427.17万，占比4.96%；增持后持股量为7774.79万，好仓比例升至5.2%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682214148","title":"港股概念追踪 | 欧洲资本组团来华扫货 中国创新药迈向海外商业化4.0时代(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682214148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682214148?lang=zh_cn&edition=full","pubTime":"2026-11-09 07:18","pubTimestamp":1794179936,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，在上海举办的“FHIM2026全球医药合作与投资年会”上，10余家欧洲生命科学投资机构的负责人组团而来，目的是挖掘中国创新药产业链中的好资产。欧洲对中国药企具备突出的战略价值。另外，从产业互补的角度看，欧洲拥有的科研积淀、产业经验与资本生态，是中国创新药实现全球化升级的重要支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0828237510.HKD","LU0359201885.HKD","BK4585","LU0307460666.USD","LU0359201612.USD","09969","LU0228659784.USD","BK1161","BK4588","BK1588","LU0359202008.SGD","LU2543165471.USD","BK1583","01276","LU1969619763.USD","01877","LU2328871848.SGD","LU1251922891.USD","BK1191","BK1574","LU1023057109.AUD","BK1500","KCAI","LU1770034418.SGD","06160","VXUS","LU1719994722.HKD","LU0588546209.SGD","LU1303224171.USD","BK1515","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197475782","title":"诺诚健华更新2026年10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1197475782","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197475782?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:43","pubTimestamp":1793868217,"startTime":"0","endTime":"0","summary":"诺诚健华医药有限公司于2026年11月5日发布2026年10月股份变动月报表，报告期截至2026年10月31日。月报显示，公司本月内未发生新的股份发行、回购或注销，股本结构保持稳定。截至报告期末，上述激励计划中部分限制性股份已失效并予以注销，未造成当月已发行股份数量的变化。截至2026年10月末，企业股本架构整体保持不变。该报告由诺诚健华医药有限公司主席兼执行董事崔霽松博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681578097","title":"诺诚健华（688428）11月4日主力资金净卖出1159.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681578097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681578097?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:27","pubTimestamp":1793838466,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，诺诚健华报收于26.05元，上涨9.78%，换手率6.18%，成交量16.91万手，成交额4.26亿元。近5日资金流向一览见下表：诺诚健华融资融券信息显示，融资方面，当日融资买入2062.88万元，融资偿还2671.26万元，融资净偿还608.37万元。诺诚健华主营业务：主要从事生物医药研发、生产和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","688428","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680367470","title":"11月4日诺诚健华涨9.78%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680367470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680367470?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:19","pubTimestamp":1793783961,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日诺诚健华涨9.78%，收盘报26.05元，换手率6.18%，成交量16.91万手，成交额4.26亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为30.0亿元，最新净值2.8021，较上一交易日下跌1.69%，近一年下跌17.01%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688428","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680036721","title":"诺诚健华涨9.78%，长城国瑞证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680036721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680036721?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:19","pubTimestamp":1793783951,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨9.78%，收盘报26.05元。2026年8月31日，长城国瑞证券研究员胡晨曦发布了对诺诚健华的研报《药品收入持续高增，自免管线兑现在即》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114419817","title":"诺诚健华：贝莱德减持，好仓比例降至4.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114419817","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114419817?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783776,"startTime":"0","endTime":"0","summary":"诺诚健华（09969）：贝莱德于2026年10月30日减持诺诚健华股份452.61万股。该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次减持前持有诺诚健华好仓7845.26万，占比5.24%；减持后持股量为7392.65万，好仓比例降至4.94%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173437548","title":"诺诚健华：贝莱德增持，好仓比例升至5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173437548","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173437548?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:24","pubTimestamp":1793697893,"startTime":"0","endTime":"0","summary":"贝莱德于2026年10月29日通过取得股份的保证权益方式场外增持诺诚健华（09969）299.53万股，该笔交易为场外交易（代价性质：非现金资产），未通过联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有诺诚健华好仓7395.13万股，占比4.94%；增持后持股量为7694.66万股，好仓比例升至5.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111874526","title":"诺诚健华：贝莱德减持，好仓比例降至4.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111874526","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111874526?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:26","pubTimestamp":1793611600,"startTime":"0","endTime":"0","summary":"贝莱德于2026年10月28日以场外方式减持诺诚健华（09969）股份246.12万股；该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次减持前持有诺诚健华好仓7641.25万，占比5.11%；减持后持股量为7395.13万，好仓比例降至4.94%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680206708","title":"诺诚健华企业传播执行总监陆春华：商业化是压舱石 全球化是必答题","url":"https://stock-news.laohu8.com/highlight/detail?id=2680206708","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680206708?lang=zh_cn&edition=full","pubTime":"2026-11-01 17:07","pubTimestamp":1793524020,"startTime":"0","endTime":"0","summary":"“全球化是必答题，不是选择题。”10月30日，由《证券日报》社主办的“大国新药价值重构——2026大健康产业大会”在杭州举行。在以“资本赋能创新医药——从估值到价值的突围”为主题的圆桌论坛环节，北京诺诚健华医药科技有限公司（以下简称“诺诚健华”）企业传播执行总监陆春华围绕创新药企从研发价值走向商业价值、从国内市场走向全球舞台的路径分享了经验与判断。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611013917726647.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611013917726647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK0239","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123429106","title":"诺诚健华：贝莱德增持，好仓比例升至5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123429106","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123429106?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:24","pubTimestamp":1793352240,"startTime":"0","endTime":"0","summary":"贝莱德于2026年10月27日通过取得股份保证权益的方式场外增持诺诚健华股份389.84万股，该笔为场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次增持前持有诺诚健华好仓7262.01万股，占比4.85%；增持后持股量为7651.85万股，好仓比例升至5.11%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679252355","title":"大行评级｜招银国际：微升诺诚健华目标价至18.9港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2679252355","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679252355?lang=zh_cn&edition=full","pubTime":"2026-10-30 10:27","pubTimestamp":1793327251,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","BK0239","09969","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678555054","title":"高盛：上调诺诚健华(09969)目标价至23.16港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678555054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678555054?lang=zh_cn&edition=full","pubTime":"2026-10-28 15:30","pubTimestamp":1793172636,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，诺诚健华第三季总收入高于该行预期，该行将H股12个月目标价由22.71港元上调至23.16港元，诺诚健华A股目标价由37.93元人民币上调至38.68元人民币，评级“买入”。诺诚健华今年第三季药物销售5.31亿元人民币(下同)，同比升39%，大致符合该行预期的5.48亿元，主要受奥布替尼持续放量带动，包括一线CLL/SLL纳入国家医保目录后的贡献，以及MZL的差异化贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","EWH","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678439972","title":"港股异动 | 诺诚健华(09969)涨超4% 前三季度实现扭亏为盈 核心产品奥布替尼持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2678439972","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678439972?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:26","pubTimestamp":1793157973,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华涨超4%，截至发稿，涨5.08%，报14.49港元，成交额3486.42万港元。消息面上，近日，诺诚健华公布2026年前三季度业绩，公司总营业收入为20.99亿元，比上年同期增长88.21%，其中药品销售收入为14.49亿元，比上年同期增长 41.47%。营业收入增长主要原因为核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增销售贡献以及公司与Zenas BioPharma,Inc.的授权许可协议完成后续里程碑交付。归属于上市公司股东的净利润约6.56亿元，同比扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688428","BK1574","BK1161","KCAI","VXUS","BK4588","09969","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","MEDX","BK0196","IE00B543WZ88.USD","09969","LNGR","LU0359201612.USD","HK0000320264.USD","KCE","LU0417516571.SGD","BK1191","LU0417516902.SGD","LU1820825898.SGD","LU1064130708.USD","LU0348767384.USD","LU2476274720.SGD","09926","LU2778985437.USD","LU0348735423.USD","600276","BK1576","BK1583","BK1589","LU1997245177.USD","BK0183","06978","LU0348827113.USD","01276","BK0188","LU1655091616.SGD","LU0634319403.HKD","06855","LU1781817850.SGD","BK1161","LU0405327148.USD","LU2097828474.EUR","LU2289578879.USD","LU1328615791.USD","159992","LU0359201885.HKD","03692","IBBQ","LU1961090484.USD","01548","01477","LU2328871848.SGD","KURE","LU0417516738.SGD","IE00B5MMRT66.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435644","title":"诺诚健华Q3营收大增150.60%：BD里程碑收入推高业绩，奥布替尼独挑商业化大梁","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435644","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678435644?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:02","pubTimestamp":1793152948,"startTime":"0","endTime":"0","summary":"本文来源：时代周报作者：曹予韩迅诺诚健华（688428.SH/09969.HK）第三季度营业收入同比大增150.60%。但同期药品销售收入增速为38.59%。两组数据出现明显剪刀差，内生盈利能力引发市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283911363089.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283911363089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678883204","title":"股市必读：诺诚健华三季报 - 第三季度单季净利润同比增长1292.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678883204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678883204?lang=zh_cn&edition=full","pubTime":"2026-10-28 03:55","pubTimestamp":1793130909,"startTime":"0","endTime":"0","summary":"截至2026年10月27日收盘，诺诚健华报收于25.16元，下跌2.25%，换手率4.69%，成交量12.82万手，成交额3.31亿元。业绩披露要点：2026年前三季度归母净利润6.56亿元，同比上升1117.93%；第三季度单季度归母净利润4.09亿元，同比上升1292.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800004018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678917232","title":"诺诚健华：10月27日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2678917232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678917232?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:01","pubTimestamp":1793102475,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年10月27日诺诚健华发布公告称公司于2026年10月27日召开业绩说明会。相关对外引进事项尚存在不确定性，请投资者注意投资风险。根据公司季度报告，2026年第三季度公司营业收入9.62亿元，其中药品销售收入5.31亿元，其余营业收入主要为公司与Zenas达成的独家许可协议所实现的里程碑收入。公司与 Zenas 的合作项目正按协议计划稳步推进，2026年第四季度及2027年，协议项下存在若干临床开发节点具备里程碑触发的潜在可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700038250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK0239","BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0836},{"period":"1month","weight":-0.0534},{"period":"3month","weight":-0.1999},{"period":"6month","weight":-0.0564},{"period":"1year","weight":-0.1591},{"period":"ytd","weight":-0.0203}],"compareEarnings":[{"period":"1week","weight":0.0438},{"period":"1month","weight":0.0143},{"period":"3month","weight":-0.0347},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0785},{"period":"ytd","weight":-0.0419}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05509},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06378},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.016143},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.062735},{"month":11,"riseRate":0.857143,"avgChangeRate":0.096587},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}